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Abstract
Background: Vedolizumab is safe and effective in adult patients with Crohn’s disease (CD) and ulcerative colitis
(UC); however, data in children with inflammatory bowel disease (IBD) are scarce. Therefore, we evaluated vedolizumab
use in a cohort of Austrian paediatric patients with IBD.
Methods: Twelve patients (7 female; 7 CD; 5 UC), aged 8–17 years (median, 15 years), with severe IBD who received
vedolizumab after tumour necrosis factor α antagonist treatment were retrospectively analysed. Clinical activity scores,
relevant laboratory parameters, and auxological measures were obtained at infusion visits.
Results: In the CD group, 1/7 patient discontinued therapy due to a severe systemic allergic reaction; 1/7 and 2/7
patients achieved complete and partial response, respectively, at week 14; and 3/7 patients discontinued therapy due
to a primary non-response or loss of response. In the UC group, complete clinical remission was achieved at weeks 2, 6,
and 14 in 2/5, 1/5 and 1/5 patients respectively; partial response was observed in one patient at week 2. CD activity
scores did not significantly change from baseline to week 38 (median 47.5 vs. 40 points, p = 1,0), while median UC
activity scores changed from 70 to 5 points (p< 0,001). Substantial weight gain and increased albumin and haemoglobin
levels were observed in both groups.
Conclusion: These results demonstrate that vedolizumab can be an effective treatment for individual paediatric patients
with IBD who are unresponsive, intolerant, or experience a loss of efficacy in other therapies. However, vedolizumab
appears to be more effective in paediatric UC than in paediatric CD.
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Background
Inflammatory bowel disease (IBD), including Crohn’s dis-
ease (CD), ulcerative colitis (UC), and unclassified IBD
(IBD-U), is a multifactorial disease that results from an
intricate interplay between genetic predisposition, altered
immune response, changes in the intestinal microbiota, and
environmental factors. Together, these factors contribute to
the destruction of the intestinal epithelial barrier, increased
gut permeability, and an influx of immune cells [1, 2].
Treatment consists of induction, maintenance therapy
and, during a flare, intensified therapy, with the aim of
achieving and maintaining clinical remission. In paediatric
CD, but not UC, exclusive enteral nutrition therapy is a
first-line treatment and is as effective as corticosteroids,
with less side effects [3]. Persistent unsatisfactory results
from treatment with immuno-modulators (such as azathi-
oprine or 6-mercaptopurine) or mesalazine and cortico-
steroids have led to the development of biologicals in the
treatment of IBD. The most common biologicals, inflixi-
mab and adalimumab, work by inhibiting the proinflam-
matory cytokine, tumour necrosis factor alpha (TNF- α),
and are effective in moderate to severe paediatric CD and
UC [4, 5]. Unfortunately, up to a third of patients do not
have a primary response, and primary responders may
develop a loss of efficacy [6]. Patients who are switched to
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a second anti-TNF- α drug are less likely to show a good
response and may develop antibodies [7].
Several novel agents are currently being investigated,
including vedolizumab, golimumab, and other biologicals
[8]. Vedolizumab is a humanized α4β7-integrin antagonist,
characterized by a gut-selective mechanism of action. By
binding to surface-expressed α4β7 integrin, it inhibits
T-lymphocyte migration into inflamed intestinal tissue.
Its efficacy and safety has been evaluated in adult patients
with moderate to severe UC and CD [9–12]. Initial data
suggest that vedolizumab exerts its full effect after 14 weeks.
Although vedolizumab was not more effective than placebo
after prior TNF- α antagonist failure in adult patients with
CD at week 6 (remission rate, 15.2%), a higher proportion
of remission was achieved with vedolizumab than with
placebo at week 10 [13]. Experience with vedolizumab
in paediatric patients is limited, as its use is off-label,
when available conventional therapy (TNF- α antago-
nists or immuno-modulators) has failed. Currently, only
two case series from the United States and one from
Europe have been published. These studies indicate a
clinical benefit of vedolizumab in the induction and
maintenance of remission in paediatric IBD, with a very
good safety profile [14–16].
The aim of this study is to complement the limited exist-
ing data by reporting the efficacy and safety of vedolizumab
in a cohort of Austrian paediatric patients with IBD.
Methods
This study was approved by the local ethics committee
(No 1140/2017) and was conducted in accordance with
the Helsinki declaration.
Study design and patient population
The present retrospective case series comprised patients
from three tertiary paediatric care centres in Austria. In
total, 12 paediatric patients with severe IBD (CD, n = 7;
UC, n = 4; IBD-U, n = 1) were started on vedolizumab
(Entyvio®, Takeda, Osaka, Japan) between November 2014
and August 2016, resulting in an observational period of
at least 38 weeks (mean duration, 52 weeks; range, 38–
96 weeks).
The indication for initiating vedolizumab treatment
was a severe disease course, with steroid dependency
and failure or intolerance of TNF-α antagonists, includ-
ing infliximab, adalimumab, and golimumab. All patients
were started on vedolizumab using a dosing regimen of
6 mg/kg, with a maximum dosage of 300 mg iv. Induction
therapy was administered in weeks 0, 2, and 6, followed by
maintenance infusions every 4–8 weeks (depending on
the disease course).
At every vedolizumab infusion visit, the short paediatric
Crohn’s disease activity index (shPCDAI) or paediatric
ulcerative colitis activity index (PUCAI) was completed, as
appropriate for the diagnosis [17, 18]. In addition, relevant
laboratory values (C-reactive protein [CRP], haemoglobin
[HB], haematocrit [HKT], and albumin) and auxological
measures (height and weight) were obtained. Fecal calpro-
tectin in UC was obtained at baseline and week 38.
Primary outcomes comprised the clinical response at
weeks 2, 6, 14, 22, and 38. Secondary outcomes included
changes in weight, height, and inflammatory marker levels.
Safety and adverse events were documented.
shPCDAI and PUCAI
As the erythrocyte sedimentation rate (ESR) was not
available at every visit, the shPCDAI index was used
[17]. The shPCDAI index was created by retaining and
re-weighting the components of the PCDAI, and assesses
general well-being, abdominal pain, weight, stools, palpa-
tion of the abdomen, and extra-intestinal manifestations.
The shPCDAI has a maximum score of 90 points; remis-
sion is defined as a score < 10 points, and scores of 10–25
points, > 25 points, and > 40 points reflect mild, moderate,
and severe disease, respectively.
The PUCAI score reflects disease activity in paediatric
UC and has a maximum score of 85 points. Remission is
defined as a score < 10 points, and scores of 10–34 points,
35–64 points, and > 65 points reflect mild, moderate, and
severe disease, respectively [18].
Statistics
Due to the small sample size and the ordinal scale of the
data, nonparametric ANOVA-type statistics were used
to compare baseline and follow-up scores, and the corre-
sponding effect measure (Relative Treatment Effect [RTE])
was calculated. Calculating the RTE is useful in studies with
a small sample size or scores that are composed of several
items, like the shPCDAI and PUCAI [19]. An RTE > 0.5
indicates a tendency towards increased scores, whereas an
RTE < 0.5 indicates a tendency towards decreased scores at
a certain time point relative to the value at baseline [20].
All p values were corrected using Bonferroni’s adjustment
for multiple testing. Adjustments were performed separ-
ately for the CD and UC groups. Secondary outcomes were
given as median and range. All calculations were performed
using R software (version, 3.3.2; R Core Team 2016).
Results
The median age of the 12 enrolled patients at baseline
was 15 years (range, 8–17 years). All patients were previ-
ously treated with infliximab, 11 patients (92%) were pre-
viously treated as well with adalimumab, and one patient
(8%) was previously treated with golimumab as a third
biologic agent. The main reason for medication discon-
tinuation was loss of response (58% for infliximab, 64% for
adalimumab). Demographic data at start of vedolizumab
treatment are shown in Table 1. Among the 7 patients
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with CD, one had neurofibromatosis type I as a second
underlying disease, one showed extra-intestinal manifesta-
tions (arthritis), and one had a perirectal fistula. None of
the patients underwent any surgery prior to vedolizumab
treatment; however, one patient with UC underwent total
colectomy after 60 weeks of treatment.
One patient discontinued therapy due to a severe gen-
eral systemic allergic reaction at the second infusion of
vedolizumab. This patient was included in the demo-
graphic data and short individual description in Tables 1
and 3, but was excluded in further investigations and
outcome data (eg. Table 2). All of the remaining 11 patients
received at least 5 vedolizumab infusions and completed
22 weeks of surveillance. Total observation and evaluation
of the clinical course was maintained until week 38.
Clinical response
In the CD cohort, 1/6 patients reached complete remission
and 2/6 had partial response at week 14. Three patients
discontinued treatment due to a primary non-response in
week 22 or a loss of response in weeks 34 and 37. In the
UC cohort, complete clinical remission was reached in 2/5
patients at week 2, 1/5 patients at week 6, and 1/5 patients
at week 14; partial response was observed in one pa-
tient at week 2. At the last follow-up, one patient with
UC underwent a total colectomy 60 weeks after the first
vedolizumab infusion due to a loss of response, steroid
dependency, and severe disease course. The shPCDAI
did not significantly change from baseline to week 38
(median 47.5 vs. 40 points, p = 1,0), while median PUCAI
changed from 70 to 5 points (p < 0,001).
The clinical activity scores for each group and the indi-
vidual courses are shown in Figs. 1 and 2. One patient in
the CD group was excluded in the comparison between
baseline and week 38 scores due to missing data. Table 3
provides an overview of the dosage, therapy duration, and
brief information regarding the individual clinical courses
until the last follow-up.
In the CD group, the RTE was 0.56 (95% CI 0.36–0.70)
at baseline, 0.46 (95% CI 0.32–0.62) at week 14, and 0.44
(95% CI 0.30–0.64) at week 38. In the UC group, the RTE
was 0.75* at baseline and 0.25* (* estimated variance = 0,
95% CI cannot be calculated) at weeks 14 and 38.
Nutritional status and laboratory values
Patients with CD showed a weight gain from 44.4 kg
(range, 31.0–62.9 kg) at baseline to 48.0 kg (range,
29.4–58.2 kg) at week 38. Considering physiological
age-depending weight gain, comparison of the mean
Z- Score at the beginning of therapy and at week 38
showed an increase from 1.05 to 1.26. The median albu-
min level increased from 29.6 g/l (range, 18.0–37.5 g/l) to
35.0 g/l (range, 28.1–42.4 g/l). The median haemoglobin
level increased from 8.4 g/dl (range, 6.9–13.0 g/dl) at base-
line to 10.5 g/dl (range, 7.8–12.3 g/dl) at week 38.
Patients with UC showed a weight gain from 34.3 kg
(range, 20.5–42.0 kg) at baseline to 44.0 kg (range, 24–
47 kg) at week 38. The median albumin level increased
from 27.9 g/l (range, 25.6–41.0 g/l) at baseline to 40 g/l
(range, 36.5–48.0 g/l) at week 38. Mean Z- Score of the
weight increased from 1.36 to 1.86. The median albumin
level increased from 27.9 g/l (range, 25.6–41.0 g/l) at
baseline to 40 g/l (range, 36.5–48.0 g/l) at week 38. The
median haemoglobin level increased from 10.4 g/dl
(range, 8.0–12.3 g/dl) at baseline to 12.1 g/dl (range,
8.0–14.8) at week 38. Median fecal calprotectin dropped
significantly in the UC cohort.
For both groups, no significant changes were observed
in height velocity, CRP and HKT levels (Table 2).
Corticosteroids and concomitant medication
In the CD group, 4/6 patients had concomitant cortico-
steroid therapy at baseline, which could be tapered down,
but not completely discontinued. In the UC cohort, 4/5
patients had corticosteroids at baseline, but the therapy
could be discontinued in all cases before week 14, but had
to be restarted in one patient before week 38. Dosage of
corticosteroids and concomitant medication including im-
munomodulators and mesalazine at baseline and week 38
Table 1 Patient characteristics at vedolizumab start
Total n (%) 12 (100)
Male n (%) 5 (42)
Type of disease n (%)
Crohn’s disease 7 (58)
Ulcerative colitis 4 (34)
Unclassified inflammatory bowel disease 1 (8)
Age yr, median (range) 15 (8–17)
Disease duration yr, median (range) 2 (1–9)
Previous biologicals n (%)
Infliximab 12 (100)
Adalimumab 11 (92)
Golimumab 1 (8)
Reasons for discontinuation
Infliximab n (%)
Primary non-responder 3 (25)
Loss of response 7 (58)
Anaphylactic reaction 2 (17)
Adalimumab n (%)
Primary non-responder 2 (18)
Loss of response 7 (64)
Local allergic reaction 2 (18)
Golimumab n (%)
Loss of respone 1 (100)
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are shown in Table 2. In the UC cohort one patient had
metronidazole at baseline, but not at week 38 and another
patient had tacrolimus at both time points (dosage per
body weight 0.1 mg vs. 0.08 mg).
Adverse events
One patient discontinued therapy due to a severe general
systemic allergic reaction with dyspnoea at the second
infusion of vedolizumab. This patient had also shown a
systemic reaction to infliximab and a local skin reaction to
adalimumab. No other infusion reactions or serious ad-
verse events were reported.
Discussion
The present study adds to the scarce literature on vedolizu-
mab use in paediatric IBD, and suggests that vedolizumab
is safe and might provide a clinical benefit. Our cohort con-
sisted of patients with refractory disease, in whom conven-
tional therapy had failed. At week 14, clinical remission was
achieved in 1/7 of the patients with CD and 4/5 of the
patients with UC. Only one patient discontinued therapy
due to a severe general systemic allergic reaction with dys-
pnoea at the second infusion of vedolizumab. These results
are consistent with previous paediatric investigations that
showed a significant reduction in activity scores only in
Table 2 Anthropometry, lab values and concomitant medication at baseline and week 38, median (range)
Baseline Week 38
Weight, kg (z score for age)
Crohn’s disease (CD) 44.4 (1.05) 48 (1.26)
Ulcerative colitis (UC) 34.3 (1.36) 44 (1.86)
Height, cm
CD 164.0 (138–172) 164.2 (140–172)
UC 146 (127–155) 148 (130–155.5)
Haemoglobin, g/dl
CD 8.4 (6.9–13.0) 10.5 (7.8–12.3)
UC 10.4 (8.0–12,3) 12.1 (8.0–14.8)
Haematocrit, %
CD 26.2 (22.9–40.1) 32.7 (25–38.3)
UC 29.6 (25.0–37.0) 35.8 (25–41.1)
Albumin, g/l
CD 29.6 (18.0–37.5) 35.0 (28.1–42.4)
UC 27.9 (25.6–41.0) 40 (36.5–48.0)
C- reactive protein, mg/dl
CD 4.0 (3.0–8.1) 2.6 (1.7–4.56)
UC 1.1 (0.1–3.0) 0.9 (0.1–2.6)
fecal calprotectin, μg/g stool
CD not applicable (n/a) n/a
UC 1482 (84–5910) 187 (5–9750)
Concomitant medication
Corticosteroids
CD, n 4/6 4/6
dosage, milligram per kilogram bodyweight (mg/KG BW) 0.25 (0.1–0.4) 0.23 (0.1–0.4)
UC, n 4/5 1/5
dosage, mg/KG BW 1 (0.5–1.5) 0.2
Azathioprine
CD, n 2/6 2/6
UC, n 1/5 1/5
Mesalazine
CD, n 2/6 2/6
UC, n 0/5 1/5
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patients with UC, with sample sizes of 64, 52, and 21, re-
spectively [14–16].
At week 14, 4/5 patients with UC achieved clinical
remission, which is comparable to the rates reported
in Singh et al. and Conrad et al. (week 14 clinical remission,
13/17 and 3/4 respectively), but is higher than that reported
in Ledder et al. (week 14 clinical remission rate, 16/34).
Although a significant reduction in the PUCAI scores was
observed by week 2, 4/5 patients had concomitant cor-
ticosteroid therapy at this time. At the last follow-up,
two patients in the UC group were still in remission;
one patient had to undergo a total colectomy due to a
severe disease course and loss of response, despite shorten-
ing of the dosing interval; and two patients presented a
variable disease course. These results are consistent with
the corticosteroid-free remission rate of 16/41 in paediatric
UC after 12 months of therapy reported in Ledder et al.
[16]. Additionally, the colectomy rate during vedolizumab
treatment is similar to that in all previous paediatric reports
(1/5, 4/22 and 6/41 respectively) [14–16]. In previous
reports, paediatric patients with CD had a poorer response
to vedolizumab therapy than patients with UC [14–16]. In
the present study, the patients in the CD cohort had longer
and more severe disease courses compared to those in the
UC cohort before the introduction of vedolizumab. This
may contribute to the lower response rate in the patients
with CD. Shelton et al. suggested that the transmural heal-
ing process in CD might take longer compared to that in
UC [21]. In addition, TNF-α antagonists downregulate
MAdCAM-1 expression; thus, patients with CD with prior
Fig. 1 Clinical activity scores using the short paediatric Crohn’s disease activity index (shPCDAI) in the CD cohort (a) and the paediatric ulcerative
colitis activity index (PUCAI) in the UC cohort (b). The dots indicate observations, which exceed the third quartile (i.e., the upper boundary of the
box) by more than 1.5 times the interquartile range
Fig. 2 Individual courses of clinical activity scores using the short paediatric Crohn’s disease activity index (shPCDAI) in the CD cohort (a) and the
paediatric ulcerative colitis activity index (PUCAI) in the UC cohort (b)
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anti-TNF exposure may require more time to respond to
treatment [13, 22].
The RTE values in the CD cohort remained similar
across the observation period, and were lower in weeks
14 (0.46) and 38 (0.44) compared to that at baseline
(0.56). Even more pronounced, RTEs in the UC cohort
dropped markedly from 0.75 at baseline to 0.25 in weeks
14 and 38. In conclusion, the RTE indicates improve-
ments in disease activity scores in the UC cohort, but
not in the CD cohort.
Regarding secondary outcomes, growth failure and nu-
tritional status in IBD patients, especially in children and
adolescents, is a big concern [23]. Particularly as body
image concerns impact the quality of life in this cohort
[24]. In our data substantial weight gain in UC and a trend
in CD was observed, while in the largest paediatric cohort
study on vedolizumab thus far, no improvement in height
velocity and no significant weight gain were observed dur-
ing treatment [16]. Height and weight were not presented
in two other paediatric studies [14, 15].
An improvement in laboratory markers, such as albu-
min and haemoglobin, were observed in both groups, rela-
tive to baseline values. In previous paediatric studies, no
relevant treatment-related changes were found in HKT, al-
bumin, and CRP levels [14]. Similarly, Singh et al. reported
a treatment-related decrease in CRP levels in patients with
CD, while CRP values were normal at baseline in the pa-
tients with UC, and albumin and HKT levels were normal
at baseline and did not change over time [15].
In the largest paediatric cohort study on vedolizumab
thus far, no improvement in height velocity and no signifi-
cant weight gain were observed during treatment, but a
decrease in faecal calprotectin was observed at the last
follow-up compared to that at baseline [16].
Regarding safety concerns and severe adverse events,
one patient, who had previously shown a systemic reaction
to infliximab and a local skin reaction to adalimumab, had
a severe systemic allergic reaction at the second infusion of
vedolizumab. No other infusion reactions or severe adverse
events were observed. Consistent with these results, minor
adverse events, but no severe adverse events or allergic
reactions, were reported in the existing paediatric studies.
Similarly, GEMINI I and II reported no severe adverse
events in adult patients, while GEMINI III reported one
(< 1%) drug-related severe adverse event [11, 13, 25].
The present study has some limitations. The study was
retrospective in nature and the sample size was small,
even though we included all paediatric patients who
received vedolizumab in Austria from November 2014
to August 2016; thus, firm conclusions on the effect of
vedolizumab cannot be drawn. In particular, it should be
emphasized that the p values and the corresponding state-
ments about statistical significance included in the present
manuscript must not be over-interpreted, since the sample
sizes are very limited. However, 8 of our patients were
followed for at least 52 weeks, which is comparable to the
study by Ledder et al. [16]. Due to the retrospective char-
acter of the study, it was not possible to include faecal
calprotectin in the CD cohort and ESR values. Prospective
long-term studies, like the currently enrolling VEDOKIDS
trial are required to define the full safety profile and
adequate dosing for vedolizumab treatment in children
with IBD [22].
Our results suggest that vedolizumab may induce a
clinical response and an improvement in soft markers,
like weight gain. However, in children with a severe dis-
ease course or steroid-dependency, a loss of response to
vedolizumab occurred quite often, and vedolizumab use
Table 3 Vedolizumab therapy in 12 patients with IBD
ID Dosage in mg Duration of therapy
at last follow up, weeks
Response and outcome of therapy
CD01 250 36 Loss of response, discontinuation in week 37
CD02 300 64 No remission achieved, dosing interval 4 weeks, variable disease course,
therapy ongoing
CD03 300 64 Remission after 14 weeks, variable disease course, therapy ongoing
CD04 300 36 Partial remission in week 14, loss of response, discontinuation in week 34
CD05 300 60 No remission achieved, variable disease course, therapy ongoing
CD06 200 16 Primary non-responder, discontinuation in week 22
CD07 300 8 Systemic allergic reaction at 2nd infusion, discontinuation
UC08 250 88 No remission achieved, variable disease course, therapy ongoing
UC09 150 96 Good response, remission, therapy ongoing
UC10 300 64 Total colectomy due to severe course of the disease 60 weeks after
vedolizumab start
UC11 300 52 Good response, remission, therapy ongoing
IBD-U12 300 52 No remission achieved, variable disease course, therapy ongoing
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was not successful in preventing a colectomy in one
child with UC.
Conclusions
In conclusion, the present study demonstrates that vedo-
lizumab might be an effective treatment for individual
paediatric patients with IBD who are unresponsive, in-
tolerant, or experience a loss of efficacy in other therapies,
including TNF-α antagonists. However, vedolizumab ap-
pears to be more effective in paediatric UC than in
paediatric CD.
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